Format

Send to

Choose Destination
J Immunol Res. 2015;2015:968212. doi: 10.1155/2015/968212. Epub 2015 Dec 16.

Clinical Options in Relapsed or Refractory Hodgkin Lymphoma: An Updated Review.

Author information

1
Hematology and Stem Cell Transplant Unit, Azienda Ospedaliera BMM, 89100 Reggio Calabria, Italy.
2
Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, 87051 Aprigliano, Italy.
3
Hematology Unit, Azienda Ospedaliera di Cosenza, 87100 Cosenza, Italy.
4
Biotechnology Research Unit, Azienda Sanitaria Provinciale di Cosenza, 87051 Aprigliano, Italy; Hematology Unit, Azienda Ospedaliera di Cosenza, 87100 Cosenza, Italy.

Abstract

Hodgkin lymphoma (HL) is a potentially curable lymphoma, and modern therapy is expected to successfully cure more than 80% of the patients. Second-line salvage high-dose chemotherapy and autologous stem cell transplantation (auto-SCT) have an established role in the management of refractory and relapsed HL, leading to long-lasting responses in approximately 50% of relapsed patients and a minority of refractory patients. Patients progressing after intensive treatments, such as auto-SCT, have a very poor outcome. Allogeneic SCT represents the only strategy with a curative potential for these patients; however, its role is controversial. Based on recent knowledge of HL pathology, biology, and immunology, antibody-drug conjugates targeting CD30, small molecule inhibitors of cell signaling, and antibodies that inhibit immune checkpoints are currently explored. This review will discuss the clinical results regarding auto-SCT and allo-SCT as well as the current role of emerging new treatment strategies.

PMID:
26788526
PMCID:
PMC4695673
DOI:
10.1155/2015/968212
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Hindawi Publishing Corporation Icon for PubMed Central
Loading ...
Support Center